Srour J, Bengel J, Linden T, et al. - In this study, a skincare cream with the transient receptor potential vanilloid type 1 inhibitor 4-t-butylcyclohexanol was evaluated for its clinical value in perioral dermatitis (POD) patients over 8 weeks. Researchers performed an open, unblinded 8-week clinical trial including 48 patients. The patients were asked to apply a skincare cream containing 4-t-butylcyclohexanol over a period of 8 weeks. During the treatment period, a significant reduction in the perioral dermatitis severity score was observed. Subjective and objective parameters of perioral dermatitis improved with this transient receptor potential vanilloid type 1 inhibitor-based skincare cream. They observed a reduction in transepidermal water loss values and increased stratum corneum hydration demonstrating the restoration of skin barrier function. Consequently, they suggest the topical inhibition of these receptors to have a promising value as a management option for POD.